CardiaTec Secures $6.5M Seed Funding to Advance Cardiovascular Drug Discovery

With this funding, CardiaTec will be able to develop its platform further and move its proprietary drug targets further to the preclinical stage

Biotech startup CardiaTec has raised $6.5 million in seed funding to further its mission of transforming cardiovascular disease treatment through high-dimensional human multi-omics data. Important figures in the industry, such as Dr. Maximilien Levesque and Naheed Kurji, as well as Continuum Health Ventures, Laidlaw Ventures, and APEX Ventures, participated in the fundraising round led by Montage Ventures.

17 million deaths worldwide are caused by cardiovascular disease each year, making it the most common cause of death worldwide. Despite the disease's widespread occurrence, medical innovation in the field has fallen short because of our incomplete knowledge of its complex biology. By using multi-omics data to find new drug targets and advance the development of differentiated treatments, CardiaTec aims to bridge this gap in the market. With this funding, CardiaTec will be able to develop its platform further and move its proprietary drug targets further to the preclinical stage. The company has set up a network of 65 hospitals in the US and UK for the collection of human heart tissue, with aim of creating the world's biggest multi-omics dataset for cardiovascular research.

CardiaTec, a 2021 spin-out from the Han Lab at the University of Cambridge, is headed by Prof. Namshik Han, CTO, and COO Thelma Zablocki with Raphael Peralta as the CEO. The team combines the expertise of industry titans such as Cleveland Clinic and Bristol Myers Squibb. CardiaTec is in the forefront of an exciting new phase in cardiovascular drug discovery owing to its advanced computational approach and solid industry partnerships.